Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
Authors:
- Sean J. BarbourSBSean J. Barbour
- Fernando C. FervenzaFFFernando C. Fervenza
- Dilshani InduruwageDIDilshani Induruwage
- Paul E. BrenchleyPBPaul E. Brenchley
- Brad RovinBRBrad Rovin
- Michelle A. HladunewichMHMichelle A. Hladunewich
- Heather N. ReichHRHeather N. Reich
- Ladan ZandLZLadan Zand
- Krzysztof KirylukKKKrzysztof Kiryluk
Top Cited Papers
- 20 July 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (10) , 1283-1293
Abstract
Background: The 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend following anti-phospholipase A2 receptor (PLA2R) antibody levels as a marker of treatment response in membranous nephropathy; however, the optimal timing to evaluate antibody levels and how to combine them with other clinical variables are currently unknown. Methods: We used a cohort of 85 patients from the Membranous Nephropathy Trial Of Rituximab (MENTOR) with anti-PLA2R antibodies ≥14 RU/ml to identify risk factors for not experiencing proteinuria remission after 12 months of treatment with cyclosporine or rituximab. Three landmark times were considered: at baseline and after 3 and 6 months of treatment. Logistic regression model performance was evaluated using C-statistics and model fit (Akaike information criterion [AIC], R2). Results: The model at baseline that best predicted no remission included anti-PLA2R antibodies >323 RU/ml and creatinine clearance; the best model after 3 months included the change from baseline in both antibody and albumin levels; and the best model after 6 months included antibody levels >14 RU/ml, creatinine clearance, and the change from baseline in albumin. Compared with the model at baseline, the model at 3 months had better model fit (AIC 70.9 versus 96.4, R2 51.8% versus 30.1%) and higher C-statistic (0.93 versus 0.83, P = 0.008). The model at 6 months had no difference in performance compared with the model at 3 months (AIC 68.6, R2 53.0%, C-statistic 0.94, P = 0.67). Conclusions: In patients with membranous nephropathy treated with cyclosporine or rituximab in the MENTOR trial, we found that the optimal method to evaluate risk factors for the probability of treatment response was to use anti-PLA2R antibody levels combined with albumin levels after 3 months of treatment, which was significantly better than using antibody levels alone or risk factor evaluation at baseline, with no added benefit of waiting until 6 months of treatment. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_10_09_CJN0000000000000237.mp3Keywords
Funding Information
- Genentech (n/a)
- Fulk Family Foundation (n/a)
- Genentech (n/a)
- Fulk Family Foundation (n/a)
This publication has 30 references indexed in Scilit:
- Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trialThe Lancet, 2013
- Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous NephropathyJournal of the American Society of Nephrology, 2011
- Have We Changed the Outcome in Membranous Nephropathy? A Propensity Study on the Role of Immunosuppressive TherapyClinical Journal of the American Society of Nephrology, 2011
- Anti-Phospholipase A2 Receptor Antibody in Membranous NephropathyJournal of the American Society of Nephrology, 2011
- An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritisNephrology Dialysis Transplantation, 2011
- Rituximab Therapy in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2010
- Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous NephropathyJournal of the American Society of Nephrology, 2010
- M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous NephropathyNew England Journal of Medicine, 2009
- Rituximab treatment of idiopathic membranous nephropathyKidney International, 2008
- Idiopathic membranous nephropathy: Definition and relevance of a partial remissionKidney International, 2004